The Life Sciences team advised Ouro Medicines on entering into a definitive agreement to be acquired by Gilead Sciences, Inc. Under the terms of the agreement, Gilead will acquire all of the outstanding equity of Ouro Medicines for a total of $1.675 billion in upfront cash consideration, subject to customary adjustments, which is payable at closing, and up to $500 million in contingent milestone payments.
Ouro Medicines is a privately held biotechnology company based in South San Francisco focused on the development of T cell engager therapies for autoimmune and inflammatory diseases. Its pipeline includes OM336 and additional preclinical programs targeting key immune pathways. OM336 is in-licensed from Keymed, which owns the rights to develop the program in the People's Republic of China and certain other jurisdictions.
The Goodwin team was led by Felipe M. Heiderich, Wei Xu, David R. Chen and Kingsley L. Taft, and included Sam Beavers, Bartek Sudol, Andrea Akinbola, Ruowen Li, Daniel Karelitz, Matthew Dunay, Katerina Stavrianidis, Kevin Kabler, Malhar Naik, Greg Matisoff, Alex Fisher, Alex Nicolaidis, Julie K. Tibbets, Matthew E. Wetzel, Arman Oruc, Anuj Ghai, Kevin Walsh, Daniel L. Farraye, Jacob Osborn, Gozde Guckaya, and Anna Sofia Polishchuk.
For more information on the deal, please read the press release.